MORROW GEORGE J 4

What Happened

• George J. Morrow, a director of Neurocrine Biosciences (NBIX), reported the conversion/exercise of 3,318 derivative units into 3,318 shares on 2026-05-21 (transaction code M). Both the acquisition and a matching disposition of 3,318 shares are reported, each at $0.00—total cash value shown as $0. The filing’s footnotes identify these instruments as Restricted Stock Units (RSUs) that were granted on May 21, 2025 and are fully vested.

Key Details

• Transaction date: 2026-05-21. Transaction code: M (exercise/conversion of a derivative).
• Shares acquired: 3,318 at $0.00. Shares disposed (derivative): 3,318 at $0.00.
• Total reported cash value: $0 (conversion/settlement entries typically show $0 price).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1—each RSU converts to one share upon vesting; F2—award granted 2025-05-21 and fully vested.
• Filing timeliness: Reported with the same period date (2026-05-21), indicating a timely Form 4 filing.

Context

• This filing documents conversion/settlement of vested RSUs rather than a market purchase or open-market sale. Converting RSUs into shares commonly results in issuance/settlement entries recorded at $0; a matching disposition line often appears when shares are surrendered or transferred at settlement (e.g., for withholding or immediate transfer), though this filing does not specify the reason. No cash proceeds or open-market trade is shown.